Impact of the learning curve on term delivery rates following laparoscopic salpingostomy for infertility associated with distal tubal occlusive disease

The objective of this study was to determine the impact of the learning curve of one surgeon on the term delivery rate following laparoscopic salpingostomy for tubal infertility. This was a retrospective audit of ongoing clinical practice, undertaken in two tertiary level infertility programmes. Subjects in this study were women undergoing surgery for total occlusion of the distal Fallopian tube. The main outcome measure was cumulative term delivery rates. On stepwise life-table analysis the length of infertility, primary and secondary infertility, tubal diameter and whether surgery was performed in the first or second half of the series were significantly associated with outcome. These data suggest that there is a learning curve in obtaining skills to perform laparoscopic salpingostomy, that patient selection may improve with experience, and that selection criteria should be emphasized during didactic teaching and the preceptorship process.      

A granulocyte reactive monoclonal antibody, 1G10, identifies the Gal beta 1-4 (Fuc alpha 1-3)GlcNAc (X determinant) expressed in HL-60 cells on both glycolipid and glycoprotein molecules

1G10, a monoclonal IgM antibody that identifies a differentiation antigen on human granulocytes and a subpopulation of monocytes, was found to react specifically with glycosphingolipids bearing the Gal beta 1-4(Fuc alpha 1-3)GlcNAc hapten (X determinant). This carbohydrate determinant was found on both glycolipid and glycoprotein molecules isolated from HL-60 cells (a promyelocytic leukemia cell line). Thus, this highly conserved carbohydrate-defined determinant previously described on mouse embryonic and mouse and human carcinoma cells is also expressed as a tissue-specific differentiation antigen on normal human granulocytes.     

First clinical use of the redesigned HeartMate II left ventricular assist system in the United States: a case report

Axial flow ventricular assist devices show great promise as a potential treatment for patients with end-stage heart failure. The HeartMate II system, redesigned on the basis of initial clinical experiences in Europe, is now in clinical trials in the United States. We report on the 1st use of the newly redesigned HeartMate II in the United States. The system has unique features, which include an accurate flow estimator and the ability to automatically detect and correct excessive left ventricular unloading. The new design also incorporates changes in the texturing of the blood-contacting surfaces to prevent thrombosis. The implantation technique and configuration are similar to those of the HeartMate XVE LVAS and require a median sternotomy for access. The 1st patient to receive the device in the United States has had an uncomplicated perioperative course and now awaits transplantation.     

Patent ductus arteriosus closure using an Amplatzer? ventricular septal defect closure device

The ductus arteriosus originates from the persistence of the distal portion of the left sixth aortic arch. It connects the descending aorta (immediately distal to the left subclavian artery) to the roof of the main pulmonary artery, near the origin of the left pulmonary artery. Persistence of the duct beyond 48 h after birth is abnormal and results in patent ductus arteriosus (PDA). PDA is rare in adults because it is usually discovered and treated in childhood. Mechanical closure remains the definitive therapy because the patency of ductus arteriosus may lead to multiple complications, depending on the size and flow through the ductus. PDA closure is indicated in patients with symptoms and evidence of left heart enlargement, and in patients with elevated pulmonary pressures when reversal is possible. Transcatheter closure is the preferred technique in adults because it avoids sternotomy, reduces the length of hospital stay and is associated with fewer complications compared with surgery. First demonstrated in 1967, both the technique and the occluder devices used have since evolved. However, designing an ideal PDA occluder has been a challenge due to the variability in size, shape and orientation of PDAs. The present article describes a case involving a 35-year-old woman who presented to the Center for Advanced Heart Failure (Houston, USA) with congestive heart failure due to a large PDA, which was successfully occluded using an Amplatzer (St Jude Medical, USA) muscular ventricular septal defect closure device. The wider waist and dual-retention discs of these ventricular septal defect closure devices may be important factors to consider in the future development of devices for the occlusion of large PDAs.     

The Canadian Chiropractic Examination Board results: a statistical evaluation

This paper presents a statistical analysis of the Canadian Chiropractic Examining Board results for the years 1977, 1978 and 1979. The examinations, of which there are 10, together with the overall result are examined from the point of view of the student’s college of graduation, the year in which the examinations were written and (for CMCC students only) prior non-chiropractic education. Finally the correlation between individual subjects and the final percent is discussed.It was found that both chiropractic college of graduation and the year in which the examinations were written were strongly related to an individual’s standing. Since it is quite possible that these results are an artifact of the examinations, arguments are put forward that the graduate population did indeed vary from year to year, and that systematic differences do exist among the graduates of the various colleges. On the other hand, however, it was found that prior non-chiropractic education had little bearing on how well a graduate did on the examinations.Although there were very strong correlations between the examinations and the final percent, four of these examinations — Neurology, Pathology, Physiology and Principles — together accounted for over 90% of the variance in the final grade.     

Myocardial thievery: the coronary-subclavian steal syndrome

Coronary-subclavian steal syndrome entails the reversal of blood flow in a previously constructed internal mammary artery coronary conduit, which produces myocardial ischemia. The most frequent cause of the syndrome is atherosclerotic disease in the ipsilateral, proximal subclavian artery. Although coronary-subclavian steal was initially reported to be rare, the increasing documentation of this phenomenon and its potentially catastrophic consequences in recent series suggests that the incidence of the problem has been underreported and that its clinical impact has been underestimated. We review the causes and background of coronary-subclavian steal; methods of preventing, diagnosing, and treating it; and the potential influence of various treatment regimens on long-term survival and the likelihood of late adverse events in patients with coronary-subclavian steal syndrome.     

The total artificial heart: where we stand

The AbioCor total artificial heart (TAH) is undergoing clinical feasibility testing as destination therapy in patients with end-stage congestive heart failure. So far, the device has been implanted in 11 of a projected 15 patients. The TAH has performed reliably, providing adequate circulatory support while extending survival and improving quality of life in most recipients. Thromboembolism remains a problem but is being addressed by optimizing device and patient management and refining the anticoagulation protocol. Because the device is totally implantable and requires no penetration of the skin, infection has been minimized. All recipients so far have been men. The device is large and this limits its use in smaller patients (i.e. women, small men and children). A smaller version is being developed. Although it has yet to receive Food and Drug Administration approval, the early clinical results suggest that the AbioCor TAH may become an accepted alternative to heart transplantation for selected patients with end-stage congestive heart failure. Further investigation with regard to its primary clinical applicability, i.e. as a rescue device for sudden catastrophic heart failure, is warranted.